Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Azacitidine, Venetoclax Combined with Chidamide (ABC-14 Regimen) As an Induction Therapy for Newly Diagnosed AML: A Real-World Retrospective Analysis By the ABC-14 Collaboration Group

Blood (2024) 144 (Supplement 1): 6014.

https://doi.org/10.1182/blood-2024-210211

Published: 2024

Journal Articles

Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)

Huafeng Wang, Xudong Wei, Yang Liang, Jianyu Weng, Wenjuan He, Chunkang Chang, Suning Chen, Hongbing Ma, Zi Chen, Lichuang Men, Lihui Liu, Xiaohong Tian, Zhang Zhang, Danhua Cong, Dajun Yang, Yifan Zhai, Jie Jin

Blood (2024) 144 (Supplement 1): 3202.

https://doi.org/10.1182/blood-2024-205371

Published: 2024

Journal Articles

Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Blood (2024) 144 (Supplement 1): 1767.

https://doi.org/10.1182/blood-2024-206453

Published: 2024

Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Qian Jiang, Li Weiming, Yanli Zhang, Qiang Wang, Suning Chen, Bingcheng Liu, Zhuogang Liu, Jie Jin, Zhenfang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Lie Lin, Wanlin Ye, Shujie Yan, Yihan Wang, Jingrong Cao

Blood (2024) 144 (Supplement 1): 477.

https://doi.org/10.1182/blood-2024-205300

Published: 2024

Journal Articles

Single-Cell Analysis Reveals Altered Tumor Microenvironments of Relapse/ Refractory and Remission-Associated Acute Myeloid Leukemia Treated By ABC-14 Regimen

Xin Huang, Minming Li, Ping Wu, Chengxin Deng, Zesheng Lu, Yulian Wang, Suxia Geng, Chengwei Luo Luo, Peilong Lai, Xin Du, Jianyu Weng

Blood (2024) 144 (Supplement 1): 5802.

https://doi.org/10.1182/blood-2024-204516

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

MRD-Driven Prophylactic or Pre-Emptive Intervention with Chidamide-Based Treatment for High-Risk AML Relapse Post-Transplantation: A Real-World Experience from a Chinese Single Center

Ping Wu, Wei Ling, Chengwei Luo Luo, Lisi Huang, Ruohao Xu, Xiaoling Liang, Jiaqi Tan, Jinghua Wang, Peilong Lai, Suijing Wu, Birong Li, Haijie Huang, Suxia Geng, Xin Du, Jianyu Weng

Blood (2024) 144 (Supplement 1): 1575.

https://doi.org/10.1182/blood-2024-210697

Published: 2024

Journal Articles

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Blood (2024) 144 (Supplement 1): 4529.

https://doi.org/10.1182/blood-2024-203533

Published: 2024

Journal Articles

Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Fang Cheng, Yu Wang, Xin Du, Yu Zhu, Jianyu Weng, Na Xu, Yunfan Yang, Jian Huang, Zhenfang Liu, Hongbo Ren, Huifang Zhao, Yajuan Ke, Weiyan Wu, Huanling Zhu, Qian Jiang, Yanli Zhang, Weiming Li

Blood (2024) 144 (Supplement 1): 4540.

https://doi.org/10.1182/blood-2024-202876

Published: 2024

Journal Articles

Treatment-Free Remission Era: BCR-ABL1 mRNA Transcript Level <5% at 3 Months Predicts 24-Month Deep Molecular Response and Better Survival

Lisi Huang, Suxia Geng, Yulian Wang, Zesheng Lu, Chengxin Deng, Xin Huang, Minming Li, Lingji Zeng, Qiong Luo, Peilong Lai, Xin Du, Jianyu Weng

Blood (2023) 142 (Supplement 1): 4545.

https://doi.org/10.1182/blood-2023-185222

Published: 2023

Journal Articles

Efficacy and Safety Analysis of Venetoclax Combined with Azacitidine in Real-World Treatment of Patients with AML

Xin Huang, Chengxin Deng, Minming Li, Zesheng Lu, Ping Wu, Qiong Luo, Suxia Geng, Lingji Zeng, Yulian Wang, Hui Zhou, Jianyu Weng, Xin Du

Blood (2023) 142 (Supplement 1): 5941.

https://doi.org/10.1182/blood-2023-186010

Published: 2023

Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

Qian Jiang, Yanli Zhang, Qiang Wang, Jianyu Weng, Zhenfang Liu, Suning Chen, Li Weiming, Bingcheng Liu, Zhuogang Liu, Yihan Wang, Jingrong Cao

Blood (2023) 142 (Supplement 1): 867.

https://doi.org/10.1182/blood-2023-185977

Published: 2023

Journal Articles

Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 2925.

https://doi.org/10.1182/blood-2023-188489

Published: 2023

Journal Articles

Chidamide-Based Pre-Emptive Treatment for High-Risk AML Patients after Hematopoietic Stem Cell Transplantation: A Real-World Experience from Chinese Single-Center

Ping Wu, Wei Ling, Chengwei Luo, Xiaomei Chen, Lisi Huang, Jinghua Wang, Peilong Lai, Suijing Wu, Xin Du, Jianyu Weng

Blood (2023) 142 (Supplement 1): 2890.

https://doi.org/10.1182/blood-2023-187924

Published: 2023

Journal Articles

ABC Regimen (Azacitidine, Venetoclax and Chidamide) Is Comparable to the “3+7” Regimen in Newly Diagnosed AML: A Real-World Experience from South China

Blood (2023) 142 (Supplement 1): 1522.

https://doi.org/10.1182/blood-2023-188196

Published: 2023

Journal Articles

Multi-Omics Reveals Azacitidine Partially Restores Hematopoiesis-Supportive Functions in Mesenchymal Stromal Cells from Patients with Chronic Myelomonocytic Leukemia

Ruohao Xu, Suxia Geng, Lingji Zeng, Chengxin Deng, Xin Huang, Minming Li, Ping Wu, Peilong Lai, Jianyu Weng, Xin Du

Blood (2023) 142 (Supplement 1): 3221.

https://doi.org/10.1182/blood-2023-189197

Published: 2023

Journal Articles

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Blood (2022) 140 (Supplement 1): 3891–3894.

https://doi.org/10.1182/blood-2022-168812

Published: 2022

Journal Articles

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Blood (2022) 140 (Supplement 1): 815–817.

https://doi.org/10.1182/blood-2022-166855

Published: 2022

Journal Articles

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael R. Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio

Blood (2022) 140 (Supplement 1): 9647–9649.

https://doi.org/10.1182/blood-2022-164444

Published: 2022

Journal Articles

Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2022) 140 (Supplement 1): 8821–8822.

https://doi.org/10.1182/blood-2022-163880

Published: 2022

NARROW

Azacitidine, Venetoclax Combined with Chidamide (ABC-14 Regimen) As an Induction Therapy for Newly Diagnosed AML: A Real-World Retrospective Analysis By the ABC-14 Collaboration Group

Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)

Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Single-Cell Analysis Reveals Altered Tumor Microenvironments of Relapse/ Refractory and Remission-Associated Acute Myeloid Leukemia Treated By ABC-14 Regimen

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

MRD-Driven Prophylactic or Pre-Emptive Intervention with Chidamide-Based Treatment for High-Risk AML Relapse Post-Transplantation: A Real-World Experience from a Chinese Single Center

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Treatment-Free Remission Era: BCR-ABL1 mRNA Transcript Level <5% at 3 Months Predicts 24-Month Deep Molecular Response and Better Survival

Efficacy and Safety Analysis of Venetoclax Combined with Azacitidine in Real-World Treatment of Patients with AML

Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms

Chidamide-Based Pre-Emptive Treatment for High-Risk AML Patients after Hematopoietic Stem Cell Transplantation: A Real-World Experience from Chinese Single-Center

ABC Regimen (Azacitidine, Venetoclax and Chidamide) Is Comparable to the “3+7” Regimen in Newly Diagnosed AML: A Real-World Experience from South China

Multi-Omics Reveals Azacitidine Partially Restores Hematopoiesis-Supportive Functions in Mesenchymal Stromal Cells from Patients with Chronic Myelomonocytic Leukemia

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only